Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 4
1947 5
1948 3
1949 6
1950 13
1951 11
1953 2
1954 1
1955 3
1956 4
1957 3
1959 2
1960 1
1961 4
1962 1
1965 1
1966 1
1967 1
1968 3
1969 3
1970 2
1971 3
1972 8
1973 6
1974 3
1975 6
1976 10
1977 4
1978 7
1979 9
1980 16
1981 8
1982 5
1983 3
1984 14
1985 6
1986 12
1987 8
1988 6
1989 9
1990 14
1991 17
1992 14
1993 13
1994 11
1995 11
1996 8
1997 21
1998 13
1999 36
2000 26
2001 36
2002 16
2003 28
2004 28
2005 32
2006 29
2007 28
2008 25
2009 33
2010 45
2011 50
2012 57
2013 54
2014 51
2015 46
2016 64
2017 74
2018 60
2019 75
2020 92
2021 84
2022 104
2023 97
2024 94

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,538 results

Results by year

Filters applied: . Clear all
Page 1
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Salles G, Duell J, González Barca E, Tournilhac O, Jurczak W, Liberati AM, Nagy Z, Obr A, Gaidano G, André M, Kalakonda N, Dreyling M, Weirather J, Dirnberger-Hertweck M, Ambarkhane S, Fingerle-Rowson G, Maddocks K. Salles G, et al. Among authors: andre m. Lancet Oncol. 2020 Jul;21(7):978-988. doi: 10.1016/S1470-2045(20)30225-4. Epub 2020 Jun 5. Lancet Oncol. 2020. PMID: 32511983 Clinical Trial.
Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.
Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi O, Lepeu G, Fruchart C, Bordessoule D, Blanc M, Delarue R, Janvier M, Salles B, André M, Fournier M, Gaulard P, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte (GELA) investigators. Peyrade F, et al. Among authors: andre m. Lancet Oncol. 2011 May;12(5):460-8. doi: 10.1016/S1470-2045(11)70069-9. Epub 2011 Apr 7. Lancet Oncol. 2011. PMID: 21482186 Clinical Trial.
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.
Fornecker LM, Lazarovici J, Aurer I, Casasnovas RO, Gac AC, Bonnet C, Bouabdallah K, Feugier P, Specht L, Molina L, Touati M, Borel C, Stamatoullas A, Nicolas-Virelizier E, Pascal L, Lugtenburg P, Di Renzo N, Vander Borght T, Traverse-Glehen A, Dartigues P, Hutchings M, Versari A, Meignan M, Federico M, André M; LYSA-FIL-EORTC Intergroup. Fornecker LM, et al. Among authors: andre m. J Clin Oncol. 2023 Jan 10;41(2):327-335. doi: 10.1200/JCO.21.01281. Epub 2022 Jul 22. J Clin Oncol. 2023. PMID: 35867960 Free article. Clinical Trial.
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.
André MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, Casasnovas O, Brice P, van der Maazen R, Re A, Edeline V, Fermé C, van Imhoff G, Merli F, Bouabdallah R, Sebban C, Specht L, Stamatoullas A, Delarue R, Fiaccadori V, Bellei M, Raveloarivahy T, Versari A, Hutchings M, Meignan M, Raemaekers J. André MPE, et al. J Clin Oncol. 2017 Jun 1;35(16):1786-1794. doi: 10.1200/JCO.2016.68.6394. Epub 2017 Mar 14. J Clin Oncol. 2017. PMID: 28291393 Clinical Trial.
Reply.
de Parisot A, Jamilloux Y, Kodjikian L, Errera MH, Sedira N, Heron E, Pérard L, Cornut PL, Schneider C, Rivière S, Ollé P, Pugnet G, Cathébras P, Manoli P, Bodaghi B, Saadoun D, Baillif S, Tieulie N, Andre M, Chiambaretta F, Bonin N, Bielefeld P, Bron A, Mouriaux F, Bienvenu B, Vicente S, Bin S, Broussolle C, Decullier E, Sève P. de Parisot A, et al. Among authors: andre m. Am J Ophthalmol. 2017 Jul;179:208-209. doi: 10.1016/j.ajo.2017.04.023. Epub 2017 May 17. Am J Ophthalmol. 2017. PMID: 28528083 No abstract available.
The authors reply.
Andre MC, Hammer J. Andre MC, et al. Pediatr Crit Care Med. 2024 Mar 1;25(3):e173-e174. doi: 10.1097/PCC.0000000000003439. Epub 2024 Mar 4. Pediatr Crit Care Med. 2024. PMID: 38451806 Free PMC article. No abstract available.
[IgG4 related disease].
Hermet M, Kémény JL, Guettrot-Imbert G, Delèvaux I, Aumaître O, André M. Hermet M, et al. Among authors: andre m. Presse Med. 2012 Jul;41(7-8):682-94. doi: 10.1016/j.lpm.2011.10.016. Epub 2011 Dec 7. Presse Med. 2012. PMID: 22154927 Free article. Review. French.
Unmet needs in the scientific approach to older patients with lymphoma.
Bron D, Aurer I, André MPE, Bonnet C, Caballero D, Falandry C, Kimby E, Soubeyran P, Zucca E, Bosly A, Coiffier B; European Lymphoma Institute (ELI) Group and the EHA SWG “Aging and Hematology”. Bron D, et al. Among authors: andre mpe. Haematologica. 2017 Jun;102(6):972-975. doi: 10.3324/haematol.2017.167619. Haematologica. 2017. PMID: 28566341 Free PMC article. Review. No abstract available.
1,538 results